Back to Search
Start Over
Certolizumab Pegol for Psoriasis and Psoriatic Arthritis
- Source :
- Current Dermatology Reports. 9:100-106
- Publication Year :
- 2020
- Publisher :
- Springer Science and Business Media LLC, 2020.
-
Abstract
- The purpose of this review is to provide an overview of the use of certolizumab pegol (Cimzia®, UCB S.A.) for psoriasis and psoriatic arthritis and summarize important findings. Three pivotal phase three clinical trials CIMPASI-1, CIMPASI-2, and CIMPACT have demonstrated efficacy and safety of certolizumab pegol (CZP) in patients with plaque psoriasis. In addition, another multicenter phase three clinical trial, RAPID-PsA, has shown long-term efficacy and safety data of CZP in psoriatic arthritis. When compared with other TNF-alpha blockers, CZP has demonstrated increased efficacy in psoriasis. In addition, CZP has also shown clinically significant and sustained improvement in psoriatic arthritis based on symptoms and radiographic evidence in patients with up to 4 years of follow-up. The safety profile of CZP is comparable to other anti-TNF agents. Finally, CZP’s unique structure as a PEGylated monoclonal antibody fragment prevents placental transfer and therefore may make it an ideal choice as a biologic medication for women of childbearing age.
- Subjects :
- Plaque psoriasis
medicine.medical_specialty
business.industry
Dermatology
medicine.disease
Clinical trial
030207 dermatology & venereal diseases
03 medical and health sciences
Safety profile
Psoriatic arthritis
0302 clinical medicine
030220 oncology & carcinogenesis
Psoriasis
Childbearing age
medicine
In patient
Certolizumab pegol
business
medicine.drug
Subjects
Details
- ISSN :
- 21624933
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Current Dermatology Reports
- Accession number :
- edsair.doi...........8317bbf6d9e99e43c2c6cea0ba8b8632